{
    "symbol": "XFOR",
    "quarter": 4,
    "year": 2022,
    "date": "2023-03-21 12:08:09",
    "content": " These proof of concept data we are generating in our Phase 1, 2 trials, aimed to unlock an even broader potential of mavorixafor, one, where we could potentially offer a differentiated oral and well tolerated treatment option to upwards of 50,000 people diagnosed with CN disorders in the U.S. We also expect to be able to provide clarity on both the scope and the possible timing of our plan Phase 3 clinical program for mavorixafor in chronic neutropenic disorders in the second or third quarter of this year."
}